KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Assets (2016 - 2025)

Sarepta Therapeutics has reported Assets over the past 15 years, most recently at $3.3 billion for Q4 2025.

  • Quarterly results put Assets at $3.3 billion for Q4 2025, down 15.48% from a year ago — trailing twelve months through Dec 2025 was $3.3 billion (down 15.48% YoY), and the annual figure for FY2025 was $3.3 billion, down 15.48%.
  • Assets for Q4 2025 was $3.3 billion at Sarepta Therapeutics, down from $3.5 billion in the prior quarter.
  • Over the last five years, Assets for SRPT hit a ceiling of $4.0 billion in Q4 2024 and a floor of $2.7 billion in Q3 2021.
  • Median Assets over the past 5 years was $3.2 billion (2021), compared with a mean of $3.2 billion.
  • Biggest five-year swings in Assets: increased 21.4% in 2024 and later decreased 15.48% in 2025.
  • Sarepta Therapeutics' Assets stood at $3.1 billion in 2021, then decreased by 0.62% to $3.1 billion in 2022, then increased by 4.35% to $3.3 billion in 2023, then grew by 21.4% to $4.0 billion in 2024, then decreased by 15.48% to $3.3 billion in 2025.
  • The last three reported values for Assets were $3.3 billion (Q4 2025), $3.5 billion (Q3 2025), and $3.7 billion (Q2 2025) per Business Quant data.